This article looks at what a transition to propellants with lower Global Warming Potential will involve and the lessons that can be learned from the industry’s earlier transition from CFCs to HFAs. Key issues that need to be addressed as formulators learn to work with propellants such as HFA 152a and HFO 1234ze include solubility of the active, the profile of the emitted spray, droplet size and evaporation, and electrostatic characteristics.
Aptar Pharma offers a comprehensive suite of services for those looking to accelerate their transition to low carbon MDIs including the Nanopharm SmartTrack™ platform which provides a wealth of information for formulation optimization.
Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery
This Might Also Be of Interest
Aptar Pharma discusses digital therapeutics for chronic conditions
Publications, Pharmaceutical, Drug Delivery Innovations, Brand Differentiation, Market Insights, Product Solutions
Roundtable: Evolution of Pressurized Metered Dose Inhalers to Cut Carbon Emissions
Webinars, Pharmaceutical, Sustainability, Drug Delivery Innovations, Market Insights, Product Solutions
Healthcare Packaging: The Future of Medical Devices
Publications, Pharmaceutical, Drug Delivery Innovations, Brand Differentiation, Market Insights, Product Solutions
Investigating The Propellant Pathways Leading To a Sustainable Future of MDIs
Publications, Pharmaceutical, Product Solutions, Sustainability, Drug Delivery Innovations
